### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type F	Responses	s)												
1. Name and Address of Reporting Person* Elefant Dov				2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 12/28/2020						X_Officer (give title below) Other (specify below) Chief Financial Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
FLORHAM	l, NJ 07													
(City)		(State)	(Zip)	Ta	ble I - No	n-Der	rivative	Securities .	Acqui	ired, Disp	osed of, or I	Beneficially (	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		(Instr. 8)		A. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					ollowing (s)	Ownership Form:	7. Nature of Indirect Beneficial	
				(Month/Day/Year)	Code	V	Amour	(A) or (D)	Price	(Instr. 3 a	nd 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common St	tock		12/28/2020		P		7,407		1.35	11,755			D	
				Derivative Securiti		cont the f	tained i form di isposed	in this for splays a c	m are curre	e not requ ntly valid	OMB conf	ormation spond unles trol number	ss	1474 (9-02)
(Instr. 3) Prid De	3. Transaction Date Exercise ice of crivative curity		Year) Execution Date	te, if Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	and (Mo	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Und Secu	itle and ount of lerlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)
				Code V	(A) (D)	Date	e rcisable	Expiration Date	Title	Amount or Number of Shares				
Reporti	ng O	wners		ı	Relationsh	ips								

## Signatures

100 CAMPUS DRIVE FLORHAM, NJ 07932

Elefant Dov

/s/ Christina Blakley, attorney-in-fact for Dov Elefant	12/28/2020		
**Signature of Reporting Person	Date		

10%

Owner

Officer

Chief Financial Officer

Other

Director

### **Explanation of Responses:**

Reporting Owner Name / Address

C/O CELLECTAR BIOSCIENCES, INC.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.